You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $36.17 in the latest trading session, marking a -0.55% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.97%. Meanwhile, the Dow lost 2.32%, and the Nasdaq, a tech-heavy index, lost 2.78%.
Coming into today, shares of the company had lost 1.57% in the past month. In that same time, the Medical sector lost 1.15%, while the S&P 500 lost 3.33%.
Wall Street will be looking for positivity from CRSP as it approaches its next earnings report date. This is expected to be March 14, 2019. Our most recent consensus estimate is calling for quarterly revenue of $3.95 million, down 87.78% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$3.21 per share and revenue of $6.63 million. These results would represent year-over-year changes of -87.72% and -83.83%, respectively.
Investors might also notice recent changes to analyst estimates for CRSP. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.11% higher. CRSP is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 98, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.